Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 2
2014 1
2016 4
2017 1
2018 2
2019 9
2020 2
2021 3
2022 5
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Results by year

Filters applied: . Clear all
Page 1
Whole-genome/exome analysis of circulating tumor DNA and comparison to tumor genomics from patients with heavily pre-treated ovarian cancer: subset analysis of the PERMED-01 trial.
Sabatier R, Garnier S, Guille A, Carbuccia N, Pakradouni J, Adelaide J, Provansal M, Cappiello M, Rousseau F, Chaffanet M, Birnbaum D, Mamessier E, Gonçalves A, Bertucci F. Sabatier R, et al. Among authors: garnier s. Front Oncol. 2022 Jul 29;12:946257. doi: 10.3389/fonc.2022.946257. eCollection 2022. Front Oncol. 2022. PMID: 35965534 Free PMC article.
Molecular Profiles of Advanced Urological Cancers in the PERMED-01 Precision Medicine Clinical Trial.
Billon E, Gravis G, Guille A, Carbuccia N, Adelaide J, Garnier S, Finetti P, Denicolaï E, Sfumato P, Brunelle S, Thomassin-Piana J, Pignot G, Walz J, Chabannon C, Pakradouni J, Sabatier R, Vicier C, Popovici C, Mamessier E, Gonçalves A, Birnbaum D, Chaffanet M, Bertucci F. Billon E, et al. Among authors: garnier s. Cancers (Basel). 2022 May 3;14(9):2275. doi: 10.3390/cancers14092275. Cancers (Basel). 2022. PMID: 35565404 Free PMC article.
Overcoming Resistance to Anti-Nectin-4 Antibody-Drug Conjugate.
Cabaud O, Berger L, Crompot E, Adélaide J, Finetti P, Garnier S, Guille A, Carbuccia N, Farina A, Agavnian E, Chaffanet M, Gonçalves A, Charafe-Jauffret E, Mamessier E, Birnbaum D, Bertucci F, Lopez M. Cabaud O, et al. Among authors: garnier s. Mol Cancer Ther. 2022 Jul 5;21(7):1227-1235. doi: 10.1158/1535-7163.MCT-22-0013. Mol Cancer Ther. 2022. PMID: 35534238
Identification of Atypical Circulating Tumor Cells with Prognostic Value in Metastatic Breast Cancer Patients.
Lopresti A, Acquaviva C, Boudin L, Finetti P, Garnier S, Aulas A, Liberatoscioli ML, Cabaud O, Guille A, de Nonneville A, Da Costa Q, Denicolai E, Pakradouni J, Goncalves A, Birnbaum D, Bertucci F, Mamessier E. Lopresti A, et al. Among authors: garnier s. Cancers (Basel). 2022 Feb 13;14(4):932. doi: 10.3390/cancers14040932. Cancers (Basel). 2022. PMID: 35205679 Free PMC article.
Circulating tumor DNA predicts efficacy of a dual AKT/p70S6K inhibitor (LY2780301) plus paclitaxel in metastatic breast cancer: plasma analysis of the TAKTIC phase IB/II study.
Sabatier R, Vicier C, Garnier S, Guille A, Carbuccia N, Isambert N, Dalenc F, Robert M, Levy C, Pakradouni J, Adelaïde J, Chaffanet M, Sfumato P, Mamessier E, Bertucci F, Goncalves A. Sabatier R, et al. Among authors: garnier s. Mol Oncol. 2022 May;16(10):2057-2070. doi: 10.1002/1878-0261.13188. Epub 2022 Mar 30. Mol Oncol. 2022. PMID: 35122700 Free PMC article. Clinical Trial.
TAKTIC: A prospective, multicentre, uncontrolled, phase IB/II study of LY2780301, a p70S6K/AKT inhibitor, in combination with weekly paclitaxel in HER2-negative advanced breast cancer patients.
Vicier C, Sfumato P, Isambert N, Dalenc F, Robert M, Levy C, Rezai K, Provansal M, Adélaïde J, Garnier S, Guille A, Carbuccia N, Popovici C, Charafe-Jauffret E, Chaffanet M, Birnbaum D, Pakradouni J, Bertucci F, Boher JM, Sabatier R, Gonçalves A. Vicier C, et al. Among authors: garnier s. Eur J Cancer. 2021 Dec;159:205-214. doi: 10.1016/j.ejca.2021.09.040. Epub 2021 Nov 12. Eur J Cancer. 2021. PMID: 34781168 Clinical Trial.
Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial.
Bertucci F, Gonçalves A, Guille A, Adelaïde J, Garnier S, Carbuccia N, Billon E, Finetti P, Sfumato P, Monneur A, Pécheux C, Khran M, Brunelle S, Mescam L, Thomassin-Piana J, Poizat F, Charafe-Jauffret E, Turrini O, Lambaudie E, Provansal M, Extra JM, Madroszyk A, Gilabert M, Sabatier R, Vicier C, Mamessier E, Chabannon C, Pakradouni J, Viens P, André F, Gravis G, Popovici C, Birnbaum D, Chaffanet M. Bertucci F, et al. Among authors: garnier s. Genome Med. 2021 May 18;13(1):87. doi: 10.1186/s13073-021-00897-9. Genome Med. 2021. PMID: 34006291 Free PMC article. Clinical Trial.
Cyclin A2 maintains colon homeostasis and is a prognostic factor in colorectal cancer.
Guo Y, Gabola M, Lattanzio R, Paul C, Pinet V, Tang R, Turali H, Bremond J, Longobardi C, Maurizy C, Da Costa Q, Finetti P, Boissière-Michot F, Rivière B, Lemmers C, Garnier S, Bertucci F, Zlobec I, Chebli K, Tazi J, Azar R, Blanchard JM, Sicinski P, Mamessier E, Lemmers B, Hahne M. Guo Y, et al. Among authors: garnier s. J Clin Invest. 2021 Feb 15;131(4):e131517. doi: 10.1172/JCI131517. J Clin Invest. 2021. PMID: 33332285 Free PMC article.
NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non-inflammatory breast cancers.
Bertucci F, Rypens C, Finetti P, Guille A, Adélaïde J, Monneur A, Carbuccia N, Garnier S, Dirix P, Gonçalves A, Vermeulen P, Debeb BG, Wang X, Dirix L, Ueno NT, Viens P, Cristofanilli M, Chaffanet M, Birnbaum D, Van Laere S. Bertucci F, et al. Among authors: garnier s. Mol Oncol. 2020 Mar;14(3):504-519. doi: 10.1002/1878-0261.12621. Epub 2020 Feb 5. Mol Oncol. 2020. PMID: 31854063 Free PMC article.
28 results